Clinical Outcomes of First-Line Immune Checkpoint Inhibitor–Based Therapy for Postoperative Recurrence After Adjuvant Nivolumab in Esophageal Cancer
Takahito Sugase, Takashi Kanemura, Norihiro Matsuura, Kei Yamamoto et autres
jp (code pays fourni par la source)